

# *N-cadherin* Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1

Nelson R. Alexander,<sup>1,2</sup> Nhan L. Tran,<sup>3</sup> Harish Rekapally,<sup>2</sup> Carol E. Summers,<sup>2</sup> Carlotta Glackin,<sup>4</sup> and Ronald L. Heimark<sup>1,2</sup>

<sup>1</sup>Cancer Biology Graduate Interdisciplinary Program, and <sup>2</sup>Departments of Surgery, and Cell Biology and Anatomy, University of Arizona Health Sciences Center, Tucson, Arizona; <sup>3</sup>Translational Genomics Institute, Phoenix, Arizona; and <sup>4</sup>Division of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California

## Abstract

The gain of *N-cadherin* expression in carcinomas has been shown to be important in the regulation of cell migration, invasion, and survival. Here, we show that *N-cadherin* mRNA expression in PC-3 prostate carcinoma cells is dependent on  $\beta_1$  integrin-mediated cell adhesion to fibronectin and the basic helix-loop-helix transcription factor Twist1. Depletion of *Twist1* mRNA by small interfering RNA resulted in decreased expression of both Twist1 and *N-cadherin* and the inhibition of cell migration. Whereas *Twist1* gene expression was independent of  $\beta_1$  integrin-mediated adhesion, Twist1 protein failed to accumulate in the nuclei of cells cultured in anchorage-independent conditions. The increased nuclear accumulation of Twist1 following cell attachment was suppressed by treatment with an inhibitor of Rho kinase or a  $\beta_1$  integrin neutralizing antibody. The effect of Twist1 on induction of *N-cadherin* mRNA required an E-box cis-element located within the first intron (+2,627) of the *N-cadherin* gene. These data raise the possibility that integrin-mediated adhesion to interstitial matrix proteins during metastasis differentially regulates the nuclear/cytoplasmic translocation and DNA binding of Twist1, activating *N-cadherin* transcription. (Cancer Res 2006; 66(7): 3365-9)

## Introduction

The *E-cadherin* gene is a common target for transcriptional repression in epithelial malignancies and its regulation is considered a key step in the metastasis of carcinomas, including breast, and prostate (1). With the silencing of *E-cadherin* transcription, adhesion molecules, such as *N-cadherin*, are induced during metastatic progression (2). Aberrant *N-cadherin* expression in carcinomas has been shown to mediate antiapoptotic signaling pathways (3), the sustained signaling of the fibroblast growth factor receptor (4), and is required for cell migration during transforming growth factor  $\beta_1$  (TGF $\beta_1$ )-stimulated epithelial-to-mesenchymal transformation (5). Although the mechanisms regulating the aberrant expression of *N-cadherin* in carcinoma progression remain unknown, the signaling of the GTPase RhoA has been shown to be necessary for *N-cadherin* induction by TGF $\beta_1$  (6). Recent evidence implicates Twist1, a basic helix-loop-helix transcription factor that is up-regulated in breast and prostate carcinomas, in the regulation of *E-cadherin* gene

expression and the enhanced expression of mesenchymal genes (7, 8). Twist has been shown to induce the expression of *N-cadherin* mRNA in human breast epithelial cells (7) but it is not known whether the expression of *Twist1* directly activates *N-cadherin* transcription in carcinomas.

Prostate tumor cells undergo dynamic changes in integrin adhesion structures as they invade the interstitial extracellular matrix to metastasize. Integrins are a family of heterodimeric adhesion that bind to matrix proteins and activate specific intracellular signal transduction pathways, reorganize the actin cytoskeleton, and regulate the nuclear/cytoplasmic shuttling of transcription factors and kinases, such as Snail and extracellular signal-regulated kinase (9, 10). A dynamic regulation of *E-cadherin* transcription by integrin-mediated cell adhesion has been shown through the downstream signaling of integrin-linked kinase (11). In this study, we document a  $\beta_1$  integrin-mediated induction of *N-cadherin* mRNA in PC-3 cells following adhesion to fibronectin. We show that *Twist1* is necessary for *N-cadherin* transcriptional activation and that Twist1 nuclear accumulation is dependent on  $\beta_1$  integrin-mediated adhesion. The regulation of *N-cadherin* expression by Twist1 is through a direct interaction with an E-box regulatory element located within the first intron of the *N-cadherin* gene.

## Materials and Methods

**Cell culture.** PC-3 and MCF-7 cells (American Type Culture Collection, Manassas, VA) were cultured in DMEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT). For anchorage-independent culture, PC-3 cells were detached with 5 mmol/L EDTA in PBS and cultured for 2 to 3 days in serum-free medium at  $10^5$  cells/cm<sup>2</sup> in dishes coated with poly-2-hydroxyethylmethacrylate (Sigma, St. Louis, MO). The wound closure assay was carried out as previously described (5) with minor modifications.

**Immunoblotting.** Nuclei were isolated by swelling cells in hypotonic buffer [10 mmol/L Tris-HCl (pH 7.4), 1 mmol/L MgCl<sub>2</sub>, 1 mmol/L EDTA] for 30 minutes on ice and shearing cells in a Dounce homogenizer. Nuclei were pelleted and lysed in Laemmli SDS sample buffer with inhibitors. Western blotting was carried out as previously described (3) with antibodies to *N-cadherin*, *E-cadherin*, and  $\beta$ -catenin (Transduction Laboratories, San Diego, CA). Polyclonal anti-Twist (H-81 and N-19) and anti-Lamin A were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Densitometry was analyzed using Scion Image.

***Twist1* small interfering RNA and overexpression.** Small interfering RNA (siRNA) against the *Twist1* target sequence 5'-ACUCCAAGAUGG-CAAGCUG-3' (nucleotides 857-875; NM000474) was purchased from Dharmacon (Lafayette, CO). siRNAs were added to cells at a final concentration of 50 nmol/L using the Oligofectamine transfection reagent (Invitrogen, Carlsbad, CA). A siRNA against the firefly luciferase target sequence 5'-CTTACGCTGAGTACTTCGA-3' was used as a negative control. The *Twist1* expression vector contains the entire coding sequence of human *Twist1* in pcDNA3.1 (12).

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

**Requests for reprints:** Ronald L. Heimark, University of Arizona Health Sciences Center, 1501 North Campbell Avenue, P.O. Box 245112, Tucson, AZ 85724. Phone: 520-626-1913; Fax: 520-626-9118; E-mail: rheimark@u.arizona.edu.

©2006 American Association for Cancer Research.  
doi:10.1158/0008-5472.CAN-05-3401

**Analysis of *E-cadherin* and *N-cadherin* mRNA levels.** Quantitative real-time PCR primers were designed using the Primer 3 software ([http://frodo.wi.mit.edu/cgi-bin/primer3/primer3\\_www.cgi](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)) and are listed in Supplementary data. For each experimental sample, transcript levels were analyzed by the  $2^{-\Delta\Delta Ct}$  method. Transcript levels were normalized to *RPL19* transcripts and were analyzed in triplicate. Northern blot analysis was completed as previously reported (13).

**Gel shift analysis.** Electrophoretic mobility shift assays were done as previously described (14). Nuclear extracts (10  $\mu$ g) were incubated with  $^{32}$ P-labeled double-stranded oligonucleotides for 15 minutes at room temperature in binding buffer [25 mmol/L HEPES (pH 7.5), 3 mmol/L  $MgCl_2$ , 1 mmol/L EDTA, 0.5% Nonidet P40, 10% glycerol] with 1  $\mu$ g of poly(dI-dC). The *N-cadherin* first intron E-box sequence (+2,619 to +2,647) oligonucleotide was 5'-GGTTAAGTGCACCATGTGGATTGTACAAC-3' whereas the mutant sequence was 5'-GGTTAAGTGCACITTTGTGGATTGTACAAC-3'. All unlabeled competitor oligonucleotides were added before incubation with labeled oligonucleotides whereas Twist1 antibodies were added 15 minutes after the labeled oligonucleotide. The *Twist1* coding sequence was subcloned in-frame into pGEX2T and the expressed protein was affinity purified. DNA protein complexes were resolved on a 5% nondenaturing polyacrylamide gel.

***N-cadherin* promoter luciferase reporter assays.** *N-cadherin* promoter activity was determined using constructs encoding the human *N-cadherin* 5' promoter (-860 to +20) in pGL3basic (Promega, Madison, WI), creating NP-860pGL3, or the 5' promoter (-860 to +20) and a region of the first intron from the human *N-cadherin* gene (+373 to +2,822 bp) downstream of luciferase in pGL3 (Supplementary data). Cells were transiently transfected in triplicate using the FuGENE 6 (Roche, Indianapolis, IN). The Dual Luciferase Kit (Promega) was used in luciferase assays according to the protocol of the manufacturer.


## Results and Discussion

**Reciprocal regulation of *E-cadherin* and *N-cadherin*.** We used the prostate adenocarcinoma cell line PC-3, which expresses both *E-cadherin* and *N-cadherin* (3), to investigate the molecular events that contribute to the induction of *N-cadherin*. To examine whether the relative cadherin gene expression was reversible, total

RNA was isolated from cells cultured in suspension as multicellular carcinoids, or from single cells attached to fibronectin. *E-cadherin* mRNA was high in suspended cells and decreased when the cells attached to a fibronectin substrate (Fig. 1A). In contrast, *N-cadherin* mRNA was 4-fold lower when cells were cultured in suspension as compared with attached cells. The protein levels of *E-cadherin* and *N-cadherin* in cells cultured in both conditions recapitulated the cadherin transcript levels (Fig. 1B). These results suggest matrix-dependent cell attachment and spreading are necessary for the dynamic regulation of *E-cadherin* and *N-cadherin* gene expression.


When suspended PC-3 carcinoids (Fig. 1C and D) were dissociated and replated onto a fibronectin substrate, the induction of *N-cadherin* mRNA level is 2-fold at 6 hours and maximal at 12 hours (Fig. 1E).  $\beta_1$  integrin colocalization with F-actin was a rapid event, visible at 30 minutes following attachment and spreading on fibronectin (Fig. 1F). Activation of *N-cadherin* gene expression was dependent on  $\beta_1$  integrin-mediated cell adhesion, as preincubation with a  $\beta_1$  integrin function-blocking antibody, AIIB2 (15), before adhesion abrogated the increase in *N-cadherin* mRNA (Fig. 1E). The reexpression of  $\beta_1$  integrin in  $\beta_1$  integrin-null epithelial cells was shown to modulate cadherin gene expression and induce an epithelial-to-mesenchymal transformation (16). Thus,  $\beta_1$  integrin-mediated signaling following cell attachment and spreading may be a mechanism regulating *N-cadherin* mRNA expression in epithelial tumors.

***Twist1* loss affects *N-cadherin* expression.** We next examined whether *Twist1* was necessary for *N-cadherin* expression in PC-3 cells attached to fibronectin. Depletion of *Twist1* mRNA with siRNA resulted in decreased expression of both *Twist1* and *N-cadherin* transcripts (Fig. 2A) and protein levels (Fig. 2B). Transfection of *Twist1* siRNAs reduced the *Twist1* mRNA levels to ~60% and *N-cadherin* transcript levels to 50%. *Twist1* protein levels were reproducibly reduced nearly 90% in each experiment and *N-cadherin* levels were 50% of the control samples. In contrast,



**Figure 1.** Dynamic regulation of *E-cadherin* and *N-cadherin* by cell adhesion to fibronectin. **A**, Northern blot analysis from total RNA for *E-cadherin*, *N-cadherin*, and *GAPDH* from PC-3 cells grown in suspension for 2 days or cells adherent to fibronectin for 24 hours ( $10^4$  cells/cm $^2$ ). **B**, Western blot analysis of *E-cadherin*, *N-cadherin*, and  $\beta$ -catenin from cells with or without the addition of serum. **C**,  $\beta$ -catenin immunofluorescence in a cross section of a multicellular carcinoid. **D**, phase photomicrograph of a multicellular carcinoid. **E**, time course of induction of *N-cadherin* transcripts following adherence to fibronectin by quantitative real-time PCR analysis. Nonimmune mouse immunoglobulin G (IgG) or the function-blocking  $\beta_1$  integrin antibody (AIIB2) was added at 5  $\mu$ g/mL before adherence. Columns, mean fold increase over *N-cadherin* expression in suspended cells; bars, SD. \*,  $P < 0.05$ . **F**, immunofluorescence of  $\beta_1$  integrin and F-actin in adherent cells at the indicated times following attachment.

**Figure 2.** *N-cadherin* transcript levels and cell migration are dependent on *Twist1* gene expression. **A**, quantitative real-time PCR analysis of *N-cadherin* and *Twist1* mRNA levels following 24-hour treatment of PC-3 cells plated on fibronectin (10  $\mu\text{g}/\text{mL}$ ) with siRNA against *Twist1* or a control *luciferase* siRNA. **B**, Western blot analysis of N-cadherin, E-cadherin, and TWIST1 protein levels following siRNA treatment of cells plated on fibronectin. **C**, representative images of 4',6-diamidino-2-phenylindole-stained nuclei of *luciferase* siRNA- and *Twist1* siRNA-treated cells following wound closure migration assay on fibronectin immediately following wounding (T-0hr) and 24 hours following wounding (T-24hrs). **D**, quantification of cell migration in wound closure assay for 24 hours. In some experiments, an irrelevant IgG or a function-blocking anti-N-cadherin monoclonal antibody (GC4) was added. Percent cell migration into wound space where the migration of control cells has been set at 100%; columns, mean of three independent experiments. \*,  $P < 0.05$ .



treatment with a control *luciferase* siRNA did not alter levels of Twist1 or N-cadherin. These findings, together with previous studies, suggest that Twist1 is necessary for the expression of *N-cadherin* in carcinoma cells (7).

Twist1 has been shown to control the migration of cancer cell lines through its ability to regulate mesenchymal gene expression (7, 8). We were interested in whether Twist1 regulation of *N-cadherin* expression contributed to cell motility in wound closure assays. As shown in Fig. 2C, control PC-3 cells or cells treated with *luciferase* siRNA efficiently migrate into the wound. In contrast, cells treated with *Twist1* siRNA have reduced migration into the wound, and cell migration is decreased by 50% (Fig. 2C and D). N-cadherin has been shown to enhance cell migration during epithelial-to-mesenchymal transformation (5). To determine the contribution of N-cadherin to PC-3 cell migration, an N-cadherin adhesion-blocking monoclonal antibody was added to cells following wounding. This resulted in a statistically significant 30% decrease in cell migration. These data are in agreement with previous studies of Twist1 expression and function in metastatic cancer cells (7, 8) and suggest that regulation of cell migration by Twist1 is, in part, through its role in induction of *N-cadherin* gene expression.

**Twist1 nuclear accumulation is integrin-mediated.** Because inhibition of  $\beta_1$  integrin engagement decreased *N-cadherin* transcript levels, we determined whether changes in *Twist1* transcript levels in anchorage-independent cells could account for the decrease in *N-cadherin* mRNA. Analysis of *Twist1* mRNA levels showed no change in the transcript level in suspended cells or in adherent cells whereas *N-cadherin* expression was up-regulated in adherent cells (Fig. 3A). In comparison, the zinc finger

transcriptional repressor *Slug* showed increased mRNA expression in adherent cells, which is consistent with its role in silencing *E-cadherin* gene expression in attached cells (17). We next examined whether Twist1 was present in the nuclei of anchorage-independent cells by subcellular fractionation. Although the level of *Twist1* mRNA did not change in suspended or adherent cells, Twist1 protein was absent from the nucleus in cells cultured in suspension (Fig. 3B). When suspended cells were replated onto a fibronectin substrate, there was a rapid accumulation of Twist1 into the nucleus, which was maximal at 30 minutes. This translocation was inhibited by addition of the  $\beta_1$  integrin neutralizing antibody, AIIB2 (Fig. 3B and C). To examine the adhesion-dependent signaling pathways downstream of the  $\beta_1$  integrin that regulate Twist1 nuclear accumulation, cells were pretreated with inhibitors before cell attachment to fibronectin. An inhibitor of Rho-associated kinase, Y-27632, and the actin-destabilizing drugs latrunculin B and jasplakinolide inhibited the nuclear accumulation of Twist1 (Fig. 3C). Consistent with the inhibition of Twist1 nuclear accumulation by Y-27632, latrunculin B, and jasplakinolide, the levels of N-cadherin were also reduced in attached and spread cells (Fig. 3D). Together these results suggest that the regulation of *N-cadherin* transcript levels by cell adhesion is due to  $\beta_1$  integrin-mediated adhesion through increased nuclear Twist1 accumulation.  $\beta_1$  integrin activation of Rho-associated kinase and actin dynamics link the extracellular microenvironment with nuclear signaling. Twist1 may therefore be a transcriptional activator modulating activity downstream of  $\beta_1$  integrin during invasion and metastasis.


**Twist1 controls *N-cadherin* promoter activity.** To determine whether the induction of *N-cadherin* mRNA by Twist1 in PC-3 cells

involves direct binding of Twist1 to a *cis*-element in the promoter of *N-cadherin*, we generated a luciferase reporter construct containing the -860 to +20 bp region of the human *N-cadherin* 5' proximal promoter (Fig. 4A). This includes the previously described minimal basal core promoter region -335 to -18 bp (18). Cotransfection of the 5' *N-cadherin* promoter construct NP860 (+860 to -20) and *Twist1* showed no increase in promoter activity in PC-3 cells nor in the *N-cadherin*- and *Twist1*-negative breast cancer cell line MCF-7 (Fig. 4B). This suggests that Twist1 has little direct or indirect effect on activity of the *N-cadherin* 5' proximal promoter. Of the two documented *Drosophila* Twist1 E-box *cis*-element sequences (CATATG or CATGTG; ref. 14), we found a potential E-box sequence CATGTG located within the first intron of the human *N-cadherin* gene at +2,627 to +2,632 bp. Incorporation of the +373 to +2,822 region of the *N-cadherin* first intron downstream of luciferase in the 5' *N-cadherin* promoter reporter construct resulted in Twist1-mediated increases in *N-cadherin* promoter activity (Fig. 4B). Mutagenesis of the E-box sequence at +2,627 eliminated the ability of Twist1 to induce *N-cadherin* promoter activity.

Electrophoretic mobility shift assays were then done to determine the ability of Twist1 to bind the putative Twist1 E-box element in the *N-cadherin* first intron. Nuclear extracts from PC-3 cells were used to determine whether endogenously expressed Twist1 could associate with the *N-cadherin* first intron E-box sequence. Three DNA-protein complexes (Fig. 4C, lane 2, C1, C2, and C3) were formed when nuclear extracts from adherent cells were incubated with labeled *N-cadherin* E-box oligonucleotides. Addition of excess unlabeled wild-type E-box oligonucleotides efficiently competed for DNA-protein complex formation whereas excess mutant oligonucleotides (TTTGTG) did not inhibit complex formation (lanes 3 and 4, respectively). To define Twist1


as the nuclear protein associating with the putative Twist1 E-box sequence, Twist1 antibody was added to the binding reactions which resulted in a supershifted DNA-protein band (lane 5). As expected, nuclear extracts from PC-3 cells in suspension failed to bind to the Twist1 E-box oligonucleotides (lane 6). A glutathione *S*-transferase (GST)-Twist1 fusion protein formed a distinct DNA-protein complex when incubated with radiolabeled *N-cadherin* E-box oligonucleotides (Fig. 4C, lane 8). This DNA-protein complex was eliminated when an excess of unlabeled wild-type oligonucleotides was added to binding reactions (Fig. 4C, lane 9). In contrast, addition of an excess of mutant oligonucleotides (TTTGTG) did not inhibit complex formation (Fig. 4C, lane 10), suggesting that Twist1 binds to the E-box sequence at +2,627 bp in the *N-cadherin* first intron. The tissue-specific regulation of *E-cadherin* gene expression was shown to involve both the first and second introns *in vivo* (19). Whereas the sequences of the first and second introns of the *E-cadherin* and *N-cadherin* genes are quite dissimilar, it seems that the intronic regulation of gene expression has been conserved between these two type I cadherin genes.

Concurrent with the loss of *E-cadherin* mRNA expression, the gain of *N-cadherin* expression in epithelial malignancies has been shown to be important in the regulation of cell migration, invasion, and survival. We provide evidence of transcriptional regulation of *N-cadherin* mRNA expression in epithelial cancer cells through an E-box sequence located within the first intron of the *N-cadherin* gene. In gastric carcinoma progression, a correlation was also described between *N-cadherin* and *Twist1* mRNA expression (20). Twist1 immunolocalization correlates with an increased Gleason score in prostate cancer specimens and displays both nuclear and cytoplasmic accumulation (8). Our work documents the  $\beta_1$  integrin-mediated control of Twist1 nuclear accumulation and



**Figure 3.** Cell adhesion to fibronectin regulates Twist1 nuclear accumulation. *A*, quantitative real-time PCR analysis of *Twist1*, *N-cadherin*, and *Slug* mRNA in adherent and nonadherent PC-3 cells. *B*, Western blot analysis of Twist1 nuclear accumulation following adherence of dissociated PC-3 carcinoids to fibronectin. *C*, Western blot analysis of Twist1 nuclear accumulation following adherence of dissociated PC-3 carcinoids to fibronectin for 30 minutes following preincubation with  $\beta_1$  integrin function-blocking antibody A1B2 (5  $\mu$ g/mL) and the inhibitors Y-27632 (50  $\mu$ mol/L), latrunculin B (1  $\mu$ mol/L), and jasplakinolide (0.5  $\mu$ mol/L). *D*, N-cadherin expression following adherence of dissociated carcinoids to fibronectin for 24 hours and treatment with Y-27632 (50  $\mu$ mol/L), latrunculin B (1  $\mu$ mol/L), and jasplakinolide (0.5  $\mu$ mol/L). Columns, mean relative densities of protein bands from three independent experiments; bars, SD.

**Figure 4.** Twist1 induces *N-cadherin* transcriptional activation through binding to an E-box regulatory element within the *N-cadherin* gene. **A**, schematic showing the potential E-box *cis*-element in intron 1 of the *N-cadherin* 5' promoter region. The ATG is designated as +1 (18). **B**, *N-cadherin* promoter activity in MCF-7 and PC-3 cells cotransfected with empty vector (pcDNA3.1) or human *Twist1*. Luciferase reporter constructs carrying the human *N-cadherin* promoter sequences: 5' proximal promoter (NP860), 5' proximal promoter with a wild-type region of the first intron of *N-cadherin* (NP860-WT Intron), or 5' proximal promoter and the segment of the *N-cadherin* first intron with a mutated E-box sequence (NP860-E-box Mutant). Luciferase activity was normalized to the activity of the pTK*Renilla* control and represented as fold over control (pcDNA3.1) for each cell line. \*,  $P < 0.005$ , MCF-7 and PC-3, respectively. **C**, electrophoretic mobility shift assay analysis with the *N-cadherin* first intron E-box oligonucleotides (WT) and nuclear extracts from adherent cells (lanes 2-5) or suspended cells (lane 6) and GST-Twist1 (lanes 8-10). Lanes 1 and 7, probe only; lane 2, adherent cell nuclear extract; lane 3, 50× WT competitor; lane 4, 50× mutant (MT) competitor (CATGTG to TTTGTG); lane 5, supershift with Twist1 antibody; lane 6, suspended PC-3 cell nuclear extract; lane 8, GST-Twist1 (100 ng); lane 9, 50× WT competitor + GST-Twist1; lane 10, 50× MT + GST-Twist1. **D**,  $\beta_1$  integrin-mediated adhesion regulates *N-cadherin* promoter activation. Cells transiently transfected with *N-cadherin* luciferase constructs were treated with irrelevant IgG or  $\beta_1$  integrin function-blocking monoclonal antibody (AIB2). Columns, percent control where IgG was set as 100%.



the transcriptional induction of *N-cadherin* mRNA. Moreover, blocking  $\beta_1$  integrin cell adhesion was found to inhibit *N-cadherin* promoter activity when the Twist1 E-box *cis*-element is present (Fig. 4D). Together these data indicate that Twist1 is a pivotal transcription factor that regulates the gene expression of *N-cadherin* during cancer metastasis through multiple mechanisms, including the direct transcriptional regulation of *N-cadherin* and the regulation of cell migration.

## Acknowledgments

Received 9/21/2005; revised 12/27/2005; accepted 2/15/2006.

**Grant support:** NIH grant PO1CA5666 and Achievement Rewards for College Scientists Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Katie Dittbenner for expert technical assistance and Drs. Richard Vaillancourt and Anne Cress for helpful discussions.

## References

- Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. *Int J Dev Biol* 2004;48:365-75.
- Tomita K, van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. *Cancer Res* 2000;60:3650-4.
- Tran NL, Adams DG, Vaillancourt RR, Heimark RL. Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. *J Biol Chem* 2002;277:32905-14.
- Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. *Cancer Cell* 2002;2:301-14.
- Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. *J Cell Sci* 2005;118:873-87.
- Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor- $\beta$ 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Mol Biol Cell* 2001;12:27-36.
- Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* 2004;117:927-39.
- Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. *Cancer Res* 2005;65:5153-62.
- Aplin AE, Stewart SA, Assoian RK, Juliano RL. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. *J Cell Biol* 2001;153:273-81.
- Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. *Cancer Res* 2005;65:3179-84.
- Wu C, Keightley SY, Leung-Hagesteijn C, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. *J Biol Chem* 1998;273:528-36.
- Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. *J Cell Biochem* 1999;75:566-77.
- Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with Stromal cells. *Am J Pathol* 1999;155:787-98.
- Lee YM, Park T, Schulz RA, Kim Y. Twist-mediated activation of the NK-4 homeobox gene in the visceral mesoderm of *Drosophila* requires two distinct clusters of E-box regulatory elements. *J Biol Chem* 1997;272:17531-41.
- Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. *J Cell Biol* 1989;109:877-89.
- Gimond C, van Der FA, van Delft S, et al. Induction of cell scattering by expression of  $\beta_1$  integrins in  $\beta_1$ -deficient epithelial cells requires activation of members of the rho family of GTPases and down-regulation of cadherin and catenin function. *J Cell Biol* 1999;147:1325-40.
- Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with snail and E47 repressors. *J Cell Sci* 2003;116:499-511.
- Le Mee S, Fromiguet O, Marie PJ. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. *Exp Cell Res* 2005;302:129-42.
- Stemmler MP, Hecht A, Kinzel B, Kemler R. Analysis of regulatory elements of E-cadherin with reporter gene constructs in transgenic mouse embryos. *Dev Dyn* 2003;227:238-45.
- Rosivatz E, Becker I, Specht K, et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. *Am J Pathol* 2002;161:1881-91.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## *N-cadherin* Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1

Nelson R. Alexander, Nhan L. Tran, Harish Rekapally, et al.

*Cancer Res* 2006;66:3365-3369.

<b>Updated version</b>	Access the most recent version of this article at: <a href="http://cancerres.aacrjournals.org/content/66/7/3365">http://cancerres.aacrjournals.org/content/66/7/3365</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2011/06/20/66.7.3365.DC1">http://cancerres.aacrjournals.org/content/suppl/2011/06/20/66.7.3365.DC1</a>

<b>Cited articles</b>	This article cites 20 articles, 12 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/66/7/3365.full#ref-list-1">http://cancerres.aacrjournals.org/content/66/7/3365.full#ref-list-1</a>
<b>Citing articles</b>	This article has been cited by 19 HighWire-hosted articles. Access the articles at: <a href="http://cancerres.aacrjournals.org/content/66/7/3365.full#related-urls">http://cancerres.aacrjournals.org/content/66/7/3365.full#related-urls</a>

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cancerres.aacrjournals.org/content/66/7/3365">http://cancerres.aacrjournals.org/content/66/7/3365</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.